Advertisement

Topics

Gilead partners with insitro for experimental liver meds

06:00 EDT 16 Apr 2019 | Pharmaceutical Manfacturing

The company is paying insitro $15 million upfront with additional near-term payments up to $35 million based on operational milestones

Original Article: Gilead partners with insitro for experimental liver meds

NEXT ARTICLE

More From BioPortfolio on "Gilead partners with insitro for experimental liver meds"

Advertisement
Quick Search
Advertisement
Advertisement